CytomX Therapeutics, Inc. (CTMX)

Market Cap	306.74M
Revenue (ttm)	141.10M
Net Income (ttm)	47.98M
Shares Out	164.91M
EPS (ttm)	0.49
PE Ratio	3.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,524,456
Open	1.900
Previous Close	1.860
Day's Range	1.770 - 2.080
52-Week Range	0.400 - 3.095
Beta	2.13
Analysts	Strong Buy
Price Target	5.67 (+219.44%)
Earnings Date	Aug 7, 2025

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBO...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2015
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: CTMX
• Website: https://www.cytomx.com

Analyst Forecast

According to 3 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $5.67, which is an increase of 219.44% from the latest price.

Price Target

$5.67

(219.44% upside)

Analyst Consensus: Strong Buy